Phase II Study of Sintilimab Combined with Ipilimumab N01, Cetuximab, and Dabrafenib in the Treatment of Microsatellite Stable, BRAF V600E-mutant Metastatic Colorectal Cancer (ChiCTR) - Oct 16, 2026 - P2 | N=49 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital
New P2 trial • Colorectal Cancer • Oncology • Solid Tumor
|